



Diagnosis and Management of Cardiovascular Disease during the COVID-19 Pandemic

Guest Editors:

Dr. Jonathan N. Bella

Department of Cardiology, Icahn
School of Medicine at Mount
Sinai, New York, NY 10029, USA

Dr. Alaa Omar

Department of Cardiology, Icahn
School of Medicine at Mount
Sinai, New York, NY 10029, USA

Deadline for manuscript
submissions:

closed (29 February 2024)

Message from the Guest Editors

Cardiac involvement has been reported in COVID-19 across all waves and all viral strains, attributed to the pandemic at all its stages. Earlier reports explained mechanisms of cardiac involvement to include coronary thromboembolism, myocardial inflammation, stress-induced cardiomyopathy, pericardial injury, and RV dysfunction. Echocardiographic studies from earlier time points in the pandemic showed that, specifically, RV dysfunction is a common finding in patients with COVID-19 and is associated with poor prognosis.

Despite the taming of the pandemic at this point in time, there are no guarantees that other strains of this virus may not be generated such that the pandemic may resurface again with significant healthcare impacts. To that extent, clinicians and healthcare facilities, despite the great level of experience in dealing with the pandemic, still have no streamlined guidelines or roadmaps for therapeutics and management options specific to and directed toward patients with COVID-19 myocardial involvement.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Giuseppe Limongelli

Department of Translational
Medical Sciences, Inherited and
Rare Heart Disease, Vanvitelli
Cardiology, University of
Campania Luigi Vanvitelli, 80131
Naples, Italy

Message from the Editor-in-Chief

Cardiogenetics is an essential resource for general physicians, cardiologists, and geneticists. Exome sequencing, noncoding DNA, bioinformatics, micro-RNA, long-noncoding DNA and epigenetics have entered our daily vocabulary, highlighting the importance of forming a “cardiogenetics team” working side by side, bringing the lab to the patients’ bed, and vice versa. A strong Editorial Board of active clinicians and scientists will support this new experience. *Cardiogenetics* publishes high-quality original research papers, review articles, short reports, news and views, with the aim of connecting the scientific (bench) to the clinical (bedside) world. Since 2011, the journal has been increasingly successful. Please help us to overcome this challenge.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [ESCI \(Web of Science\)](#), [Scopus](#), [Embase](#), and [other databases](#).

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 23.1 days after submission; acceptance to publication is undertaken in 6.2 days (median values for papers published in this journal in the second half of 2025).

Contact Us

Cardiogenetics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cardiogenetics
cardiogenetics@mdpi.com
[X@CardiogenMDPI](#)